Ablynx

@AblynxABLX

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies® for a range of serious human diseases.

Ghent/Zwijnaarde, Belgium
Inscrit en mai 2012

Tweets

Vous avez bloqué @AblynxABLX

Êtes-vous sûr de vouloir voir ces Tweets ? Les voir ne débloquera pas @AblynxABLX

  1. a retweeté
    26 juil.

    FDA designates top nanobody caplacizumab fast track designation: 6-10 months faster approval

  2. a retweeté
    20 juil.
  3. 20 juil.

    and Sanofi to develop up to 8 Nanobody®-based therapeutics focused on immuno-inflammatory diseases

  4. 27 juin

    achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc.

  5. 26 juin

    initiates a single and multiple dose Phase I study of caplacizumab in healthy Japanese subjects

  6. 29 mai

    launches , a new website dedicated to Thrombotic Thrombocytopenic Purpura (TTP)

  7. 22 mai

    receives €15M milestone from Merck KGaA for novel Nanobody in osteoarthritis

  8. 18 mai

    Meet our experts and recruiters (booth 99) @

  9. 11 mai
  10. 11 mai

    Q1 2017 "Positive start of the year; good progress in multiple programmes; strong cash position"

  11. 10 mai

    Publication in Journal of Thrombosis and Haemostasis "Caplacizumab reduces major thromboembolic events"

  12. 2 mai

    successfully completes patient recruitment in its Phase III Hercules study of caplacizumab

  13. 7 avr.

    Annual Report 2016 is available online - view via

  14. 7 avr.
  15. a retweeté
    6 mars

    Compelling data for developed psoriasis nanobody in collaboration

  16. a retweeté
    28 févr.

    Good morning to those waking up in Europe, Africa and the Middle East! Share with us what you have planned for today!

  17. a retweeté
    24 févr.

    you will find out that is dedicated to creating new medicines which will make a real difference to society!

  18. 23 févr.

    FYR 2016: significant progress in R&D pipeline; strong cash position; major catalysts in 2017.

  19. 9 févr.

    will present additional data from the Phase IIb RA combination study of vobarilizumab at the Annual CRA Meeting

  20. 6 févr.

Le chargement semble prendre du temps.

Twitter est peut-être en surcapacité ou rencontre momentanément un incident. Réessayez ou rendez-vous sur la page Twitter Status pour plus d'informations.

    Vous aimerez peut-être aussi

    ·